Knowledge Library

Pharmacodynamic and Pharmacokinetic Profile of a Novel GLP-1 Receptor Biased Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >

Resource Type: Latest Science, Publication
Resource Topic: Candidate Selection, Metabolic Diseases, Small Molecules

VIEW

Xenograft and Syngeneic Tumor Models in Rats

Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared with mice include: more similar metabolism and physiology to human; easier use for orthotopic model surgery, vascular manipulation, and imaging; larger sampling sizes to ensure sufficient amount for bioanalysis; consistent animal species to toxicology studies …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Candidate Selection, Oncology, Tumor Models

VIEW

OncoWuXi Newsletter December 2022

Resource Type: Latest Science, Newsletter
Resource Topic: Autoimmune and Inflammatory Diseases, Biochemical Assays, Biomarkers, Candidate Selection, Cell-based Assays, DRUG DISCOVERY AND INNOVATION, Hit Finding, Hit-to-Lead, Immunology, Lead Optimization, Oncology, Phenotypic Assays, Rare Diseases, Target Identification and Validation, Tumor Models

VIEW

WuXi AppTec Oligonucleotide Biology Platform

We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays, Candidate Selection, Cell-based Assays, Discovery Chemistry, Gene Therapies, Hit-to-Lead, in vivo Pharmacology, Lead Optimization, Liver Diseases, Oligonucleotides, Rare Diseases, Safety and Early Toxicity, Target-Specific Assays

VIEW

Oligonucleotide Drug Development (CMC)

Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. During this webinar …Read More >

Resource Type: Webinar
Resource Topic: Candidate Selection, Oligonucleotides

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Autoimmune and Inflammatory Diseases, Biochemical Assays, Biomarkers, Biophysical Assays, Candidate Selection, CAR-T Cell, Cardiovascular & Metabolic Diseases, Cell Therapies, Cell-based Assays, Cells and Protein Science, Central Nervous System & Pain, Chemical Biology and Proteomics, Dermatology, Discovery Chemistry, DNA-Encoded Library (DEL), DRUG DISCOVERY AND INNOVATION, Fragment-Based Drug Discovery, Gene Therapies, High-throughput screening (HTS), Hit Finding, Hit-to-Lead, Immunology, in silico services, in vitro biology, in vivo Pharmacology, in vivo Toxicology, Infectious Diseases, Lead Optimization, Liver Diseases, Mass Spectrometry-based Assays, Metabolic Diseases, NASH, Oligonucleotides, Oncology, Oncolytic Viruses, Ophthalmology, Phenotypic Assays, Quantum Mechanics, Rare Diseases, Respiratory Diseases, Safety and Early Toxicity, Screening Libraries, Screening Services, Small Molecules, Structural Biology, Target Identification and Validation, Target-Specific Assays, Targeted Protein Degradation, TECHNOLOGY PLATFORMS, THERAPEUTIC AREAS, THERAPEUTIC MODALITIES, Tumor Models

VIEW

Quantitative Histopathology of Fibrosis in an Animal Model of NASH

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >

Resource Type: Article, Blog
Resource Topic: Biomarkers, Candidate Selection, Liver Diseases, Metabolic Diseases, NASH

VIEW

Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.

Resource Type: Newsletter
Resource Topic: Candidate Selection, Cell-based Assays, Hit-to-Lead, Immunology, Lead Optimization, Oncology, Tumor Models

VIEW

Outsourcing Drug Discovery and Development: Considerations For Emerging Biopharma Companies

Resource Type: White Paper
Resource Topic: Candidate Selection, Discovery Chemistry, DRUG DISCOVERY AND INNOVATION, Hit Finding, Hit-to-Lead, Lead Optimization, Target Identification and Validation

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!